NCT04542291View on ClinicalTrials.gov

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

December 24, 2021

Study Completion Date

January 19, 2022

Conditions
Pancreas CancerPancreatic CancerCancer of the Pancreas
Interventions
DRUG

Dapagliflozin

Dapagliflozin will be provided for this trial

DEVICE

BIOSENSE meters

-Being used in this trial to evaluate utility for assessing breath ketones

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT04542291 - Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition | Biotech Hunter | Biotech Hunter